Zhejiang Ausun Pharmaceutical Co., Ltd.
SHH: 603229.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhiguo Zheng
- Employees
- 1,174
- Headquarters
- Linhai, China
- IPO year
- 2017
- Market cap
- CN¥8.4B
- Website
- https://www.ausunpharm.com
Loading 603229…
Loading profile data…Frequently asked questions about 603229
What does Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) do?
Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indication...
Where does 603229.SS trade?
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) trades on the Shanghai Stock Exchange.
What sector is 603229.SS in?
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zhejiang Ausun Pharmaceutical Co., Ltd.?
Zhiguo Zheng is the chief executive officer of Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS).
Where is Zhejiang Ausun Pharmaceutical Co., Ltd. headquartered?
Zhejiang Ausun Pharmaceutical Co., Ltd. is headquartered in China.
Does 603229.SS pay a dividend?
Yes — Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) paid a trailing twelve-month dividend of CNY 0.10 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603229.SS go public?
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) completed its initial public offering in 2017.